3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Small Cell
1
Interventions
Paclitaxel
10
Radiotherapy
7
Fluorouracil
7
pembrolizumab
6
Carboplatin
6
Oxaliplatin
5
Cisplatin
5
lenvatinib
3
Neoadjuvant Therapy
3
Cetuximab
3
tislelizumab
2
camrelizumab
2
Surgical Procedures, Operative
2
Nivolumab
2
Leucovorin
2
Irinotecan
2
Drug Therapy
2
Docetaxel
2
tremelimumab
1
toripalimab
1
regorafenib
1
osimertinib
1
oblimersen
1
nimotuzumab
1
nedaplatin
1
monalizumab
1
enzalutamide
1
durvalumab
1
aflibercept
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Esophageal Squamous Cell Carcinoma
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled